Company
Sarcio
Advanced exosome biologics to regenerate, repair and restore.
Also known as SARCIO, INC.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- SARCIO, INC.
Claim, correct or request removal
Record updated 28 September 2026
About
Sarcio has developed a proprietary platform technology that utilizes induced pluripotent stem cells (iPSCs) to grow cartilage tissue, creating a robust source of exosomes that carry regenerative signals to promote healing and repair in osteoarthritic joints.
Funding snapshot
- Total raised
- $1.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $608K2021-12-21
Funding rounds
- Round, 2021
- $608K2021-12-21, SEC form D sold, 13 investors
- Round, 2021
- $785K2021-03-05, SEC form D sold, 23 investors
Loading relationship preview